Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment

L.M Monteiro, Raimar Löbenberg, Nikoletta Fotaki, Gabriel Lima Barros de Araujo, P.C Cotrim, Nádia Araci Bou-Chacra

Research output: Contribution to journalArticle

Abstract

Objectives: This study aimed to describe the preparation and in vitro evaluation of a surface-modified nanostructured lipid carrier (NLC) using chitosan and dextran for co-delivery of buparvaquone (BPQ) and polymyxin B (PB) against leishmaniasis. Methods: The NLC was prepared using high-pressure homogenisation. Polymyxin B binding and surface modification with biopolymers were achieved by electrostatic interaction. In vitro cytotoxicity was assessed in mouse peritoneal macrophages, and leishmanicidal activity in amastigotes of Leishmania infantum. Results: The performance attributes of BPQ-NLC, BPQ-NLC-PB[A ] (anionic) and BPQ-NLC-PB[C +] (cationic) were respectively: Z-average 173.9 ± 1.6, 183.8 ± 4.5 and 208.8 ± 2.6 nm; zeta potential −19.6 ± 1.5, −20.1 ± 1.1 and 31.1 ± 0.8 mV; CC 50 583.4 ± 0.10, 203.1 ± 0.04 and 5.7 ± 0.06 μM; IC 50 229.0 ± 0.04, 145.7 ± 0.04 and 150.5 ± 0.02 nM. The NLC in vitro leishmanicidal activity showed up to 3.1-fold increase when compared with free BPQ (P < 0.05, α = 0.05). Conclusions: The developed NLC proved to be a promising formulation with which to overcome the drawbacks of current leishmaniasis treatment by the co-delivery of two alternative drugs and a macrophage targeting modified surface.

Original languageEnglish
Pages (from-to)279-283
Number of pages5
JournalJournal of Global Antimicrobial Resistance
Volume18
Early online date13 Jun 2019
DOIs
Publication statusPublished - 1 Sep 2019

Keywords

  • Buparvaquone
  • Chitosan
  • Dextran
  • Leishmaniasis
  • Nanostructured lipid carrier
  • Polymyxin B

ASJC Scopus subject areas

  • Microbiology
  • Immunology and Allergy
  • Immunology
  • Microbiology (medical)

Cite this

Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. / Monteiro, L.M; Löbenberg, Raimar; Fotaki, Nikoletta; Barros de Araujo, Gabriel Lima; Cotrim, P.C; Bou-Chacra, Nádia Araci.

In: Journal of Global Antimicrobial Resistance, Vol. 18, 01.09.2019, p. 279-283.

Research output: Contribution to journalArticle

Monteiro, L.M ; Löbenberg, Raimar ; Fotaki, Nikoletta ; Barros de Araujo, Gabriel Lima ; Cotrim, P.C ; Bou-Chacra, Nádia Araci. / Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. In: Journal of Global Antimicrobial Resistance. 2019 ; Vol. 18. pp. 279-283.
@article{3a9f2b162bd940ccaaf60879bb2a574f,
title = "Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment",
abstract = "Objectives: This study aimed to describe the preparation and in vitro evaluation of a surface-modified nanostructured lipid carrier (NLC) using chitosan and dextran for co-delivery of buparvaquone (BPQ) and polymyxin B (PB) against leishmaniasis. Methods: The NLC was prepared using high-pressure homogenisation. Polymyxin B binding and surface modification with biopolymers were achieved by electrostatic interaction. In vitro cytotoxicity was assessed in mouse peritoneal macrophages, and leishmanicidal activity in amastigotes of Leishmania infantum. Results: The performance attributes of BPQ-NLC, BPQ-NLC-PB[A −] (anionic) and BPQ-NLC-PB[C +] (cationic) were respectively: Z-average 173.9 ± 1.6, 183.8 ± 4.5 and 208.8 ± 2.6 nm; zeta potential −19.6 ± 1.5, −20.1 ± 1.1 and 31.1 ± 0.8 mV; CC 50 583.4 ± 0.10, 203.1 ± 0.04 and 5.7 ± 0.06 μM; IC 50 229.0 ± 0.04, 145.7 ± 0.04 and 150.5 ± 0.02 nM. The NLC in vitro leishmanicidal activity showed up to 3.1-fold increase when compared with free BPQ (P < 0.05, α = 0.05). Conclusions: The developed NLC proved to be a promising formulation with which to overcome the drawbacks of current leishmaniasis treatment by the co-delivery of two alternative drugs and a macrophage targeting modified surface.",
keywords = "Buparvaquone, Chitosan, Dextran, Leishmaniasis, Nanostructured lipid carrier, Polymyxin B",
author = "L.M Monteiro and Raimar L{\"o}benberg and Nikoletta Fotaki and {Barros de Araujo}, {Gabriel Lima} and P.C Cotrim and Bou-Chacra, {N{\'a}dia Araci}",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jgar.2019.06.006",
language = "English",
volume = "18",
pages = "279--283",
journal = "Journal of Global Antimicrobial Resistance",
issn = "2213-7165",
publisher = "Elsevier",

}

TY - JOUR

T1 - Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment

AU - Monteiro, L.M

AU - Löbenberg, Raimar

AU - Fotaki, Nikoletta

AU - Barros de Araujo, Gabriel Lima

AU - Cotrim, P.C

AU - Bou-Chacra, Nádia Araci

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objectives: This study aimed to describe the preparation and in vitro evaluation of a surface-modified nanostructured lipid carrier (NLC) using chitosan and dextran for co-delivery of buparvaquone (BPQ) and polymyxin B (PB) against leishmaniasis. Methods: The NLC was prepared using high-pressure homogenisation. Polymyxin B binding and surface modification with biopolymers were achieved by electrostatic interaction. In vitro cytotoxicity was assessed in mouse peritoneal macrophages, and leishmanicidal activity in amastigotes of Leishmania infantum. Results: The performance attributes of BPQ-NLC, BPQ-NLC-PB[A −] (anionic) and BPQ-NLC-PB[C +] (cationic) were respectively: Z-average 173.9 ± 1.6, 183.8 ± 4.5 and 208.8 ± 2.6 nm; zeta potential −19.6 ± 1.5, −20.1 ± 1.1 and 31.1 ± 0.8 mV; CC 50 583.4 ± 0.10, 203.1 ± 0.04 and 5.7 ± 0.06 μM; IC 50 229.0 ± 0.04, 145.7 ± 0.04 and 150.5 ± 0.02 nM. The NLC in vitro leishmanicidal activity showed up to 3.1-fold increase when compared with free BPQ (P < 0.05, α = 0.05). Conclusions: The developed NLC proved to be a promising formulation with which to overcome the drawbacks of current leishmaniasis treatment by the co-delivery of two alternative drugs and a macrophage targeting modified surface.

AB - Objectives: This study aimed to describe the preparation and in vitro evaluation of a surface-modified nanostructured lipid carrier (NLC) using chitosan and dextran for co-delivery of buparvaquone (BPQ) and polymyxin B (PB) against leishmaniasis. Methods: The NLC was prepared using high-pressure homogenisation. Polymyxin B binding and surface modification with biopolymers were achieved by electrostatic interaction. In vitro cytotoxicity was assessed in mouse peritoneal macrophages, and leishmanicidal activity in amastigotes of Leishmania infantum. Results: The performance attributes of BPQ-NLC, BPQ-NLC-PB[A −] (anionic) and BPQ-NLC-PB[C +] (cationic) were respectively: Z-average 173.9 ± 1.6, 183.8 ± 4.5 and 208.8 ± 2.6 nm; zeta potential −19.6 ± 1.5, −20.1 ± 1.1 and 31.1 ± 0.8 mV; CC 50 583.4 ± 0.10, 203.1 ± 0.04 and 5.7 ± 0.06 μM; IC 50 229.0 ± 0.04, 145.7 ± 0.04 and 150.5 ± 0.02 nM. The NLC in vitro leishmanicidal activity showed up to 3.1-fold increase when compared with free BPQ (P < 0.05, α = 0.05). Conclusions: The developed NLC proved to be a promising formulation with which to overcome the drawbacks of current leishmaniasis treatment by the co-delivery of two alternative drugs and a macrophage targeting modified surface.

KW - Buparvaquone

KW - Chitosan

KW - Dextran

KW - Leishmaniasis

KW - Nanostructured lipid carrier

KW - Polymyxin B

UR - http://www.scopus.com/inward/record.url?scp=85070869761&partnerID=8YFLogxK

U2 - 10.1016/j.jgar.2019.06.006

DO - 10.1016/j.jgar.2019.06.006

M3 - Article

VL - 18

SP - 279

EP - 283

JO - Journal of Global Antimicrobial Resistance

JF - Journal of Global Antimicrobial Resistance

SN - 2213-7165

ER -